DRUG-RESISTANT TUBERCULOSIS

Аннотация

This article provides information about drug-resistant tuberculosis (MDR-TB). Drug-resistant tuberculosis occurs when mycobacteria become resistant to the main antituberculosis drugs. This disease, unlike regular tuberculosis, is much more difficult to treat and requires long-term special drugs. The article provides detailed information about theclinical signs, diagnosis, treatment methods and prevention of drug-resistant tuberculosis. Early detection and proper treatment of tuberculosis are important in preventing drug- resistant forms oftuberculosis. Keywords: Drug-resistant tuberculosis, Tuberculosis, MDR-TB Mycobacteria, Antituberculosis drugs, Tuberculosis, Resistant mycobacteria, Clinical signs of tuberculosis, Diagnostics, Treatment methods,Prophylaxis, Prevention oftuberculosis. Drug-resistant tuberculosis (or drug-resistant tuberculosis — MDR-TB) is a form of tuberculosis with a unique characteristic. It is a type of mycobacterium tuberculosis that is resistant to drugs. In this case, patients become resistant to standard antituberculosis drugs, such as isoniazid and rifampicin. As a result, the disease becomes much more difficult to treat. Key features ofdrug-resistant tuberculosis: Resistance: Drug-resistant tuberculosis occurs when mycobacterial strains have become naturally or artificially resistant to standard antituberculosis drugs. It develops, in particular, as a result of improper treatment, drug shortages, or the patient's discontinuation of treatment. Clinical signs: Signs of drug-resistant tuberculosis include typical symptoms of tuberculosis, such as:  Persistentcough  Severeshortness ofbreath  Changes in appetite  Fatigue, pain  High bodytemperature Diagnosis: Specific laboratory tests and genetic tests, such as the Xpert MTB/RIF test or moleculardiagnostic methods,are used todetect drug-resistant tuberculosis. Treatment: Treatment of drug-resistant tuberculosis requires more and stronger drugs. This treatment process can be more time-consuming, complicated, and can affect the patient's body. Treatment usuallylasts 18-24 monthsandinvolves different drugs. 98,7:ROTCAFTCAPMI.SECNEICS LACIDEM,5202, yraurbeF,5emuloV gro.srehsilbupcimedaca.www Prevention: To prevent drug-resistant tuberculosis, it is important to detect tuberculosis at an early stage and treat it correctly. It is important for all tuberculosis patients to take their medications correctly and complete thefull course ofmedication. Multidrug-resistant tuberculosis (MDR-TB) is a global health problem, as it makes treatment moredifficult and requires moreresources. Therefore, effective social andmedical systems are needed tocombat it. Multidrug-resistant tuberculosis (MDR-TB) is a global health problem, and new research and approaches to its prevention and treatment are constantly being developed. The followingare thelatestscientific developments and additional information: 1.Newtreatment regimens: The TB PRACTECAL project is developing new, shorter and more effective treatment regimens for the treatment of drug-resistant tuberculosis. These regimens, consisting of bedaquiline, pretomanid, linezolid and moxifloxacin, have been shown to be safer and more effectivethan current standard treatments. 2.Improved diagnosticmethods: Diagnostic methods are improving for the early detection of drug-resistant tuberculosis. For example, rapid molecular tests such as GeneXpert are able to quickly identify tuberculosis andits drug-resistant variants. However, in somecountries, such as Pakistan, more than 75% ofdrug-resistant tuberculosis cases are undetected. 3.Shorteningthe duration oftreatment: Traditionally, treatment for drug-resistant tuberculosis has taken 18-24 months, but new research is exploring the possibility of shortening the duration of treatment. This will help improvethequality oflifeof patientsand reducethecost oftreatment. 4.Preventivemeasures: Preventive measures are essential to prevent drug-resistant tuberculosis, including early detection and proper treatment of patients with tuberculosis, as well as regular screening and protection ofhealth workers. 5.Global cooperation and resources: Global cooperation and resource sharing are essential in combating drug-resistant tuberculosis. International organizations, including the World Health Organization (WHO) and Médecins Sans Frontières (MSF), are implementing global initiatives to treat and prevent drug-resistant tuberculosis. New scientific research and innovative approaches play a key role in combating drug- resistant tuberculosis. However, a global concerted effort is needed to completely eliminate this disease. Multidrug-resistant tuberculosis (MDR-TB) is a global health threat that is 98,7:ROTCAFTCAPMI.SECNEICS LACIDEM,5202, yraurbeF,5emuloV gro.srehsilbupcimedaca.www difficult and time-consuming to treat. New research and innovative treatments are helping to manage the disease, and new short-term treatment regimens and rapid diagnostic methods arebeing developed.